Evolocumab + biosimilar in development?

Are you asking whether an evolocumab (Repatha) biosimilar is in development, or are you looking for specific company/phase/regulatory status for a particular candidate?

Here’s the high-level, up-to-date landscape:

• Evolocumab is a PCSK9 monoclonal antibody (brand: Repatha).
• Biosimilars require extrapolation and demonstrate “similarity” in key domains (structure, function, PK/PD, and clinical outcomes).
• As of my latest knowledge, there have been multiple efforts globally to develop evolocumab biosimilars, but the exact number of products/ongoing trials and which have reached which regulatory stage depends on the region (FDA/EMA/others) and changes over time.

If you want, I can narrow it down quickly

Reply with any one of the following and I’ll pull together the most relevant “in development” details:

1. Country/region (US, EU, UK, India, etc.)
2. The company name (if you have one)
3. Whether you mean clinical trials vs regulatory submission
4. Your preferred output format (table with phase/status, or a short narrative)

What region are you interested in?